Single CRISPR Treatment Halves 'Bad' Cholesterol for a Year in Clinical Trial

A first-in-human Phase 1 clinical trial conducted by Cleveland Clinic has shown that a single infusion of an experimental CRISPR-Cas9 gene-editing therapy significantly reduced LDL ('bad') cholesterol and triglycerides by about half in patients with lipid disorders unresponsive to conventional medications. These reductions were sustained for a full year, with the highest dose leading to a 52.5% drop in LDL cholesterol and a 47.8% decrease in triglycerides. The findings were presented at the 2026 European Society of Cardiology annual meeting and simultaneously published in The New England Journal of Medicine.

Context

Cleveland Clinic's Phase 1 clinical trial is the first to test a CRISPR-Cas9 gene-editing therapy in humans for lipid disorders. LDL cholesterol is often referred to as 'bad' cholesterol, and high levels are linked to increased risk of heart disease. Previous treatments have limitations, particularly for patients who do not respond to standard therapies.

Why it matters

The reduction of LDL cholesterol is crucial for preventing cardiovascular diseases, which are a leading cause of death globally. Traditional treatments may not work for all patients, making this CRISPR therapy a potential game-changer. Sustained effects over a year suggest long-term benefits and could reduce the need for ongoing medication.

Implications

If successful, this therapy could significantly impact patients with high cholesterol who do not respond to existing treatments. It may also influence the development of other gene-editing therapies for various conditions. Healthcare providers may need to adapt treatment protocols based on the availability of this new option.

What to watch

Future studies will likely focus on larger patient populations to confirm these results and assess long-term safety. Regulatory approvals will be necessary before this treatment can become widely available. Monitoring for any adverse effects or complications during the extended follow-up period will be critical.